Further it is known that C3 is upregulated in the retina of AMD patients65,66, as well as vitreous, aqueous and serum of uveitis patients67–69, thus, targeting the complement system presents an attractive approach to treat retinopathies70. This evidence concerns the gene C3 and uveitis.